Cover Image
Market Research Report

Biomedtracker / Meddevicetracker Q3 2020 Outlook Report

Published by Datamonitor Healthcare Product code 955915
Published Content info 52 Pages
Delivery time: 1-2 business days
Price
Back to Top
Biomedtracker / Meddevicetracker Q3 2020 Outlook Report
Published: July 1, 2020 Content info: 52 Pages
Description

Overview

In this report, we cover catalysts from 27 drugs, devices, diagnostics and deals expected to occur in Q3 2020. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa's drug development benchmarking product utilizing Biomedtracker's LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker. The results of the drug catalysts highlighted in our Biomedtracker / Meddevicetracker Q2 2020 Outlook Report can be found on Page 6. At the end of this report, we have included a list of Large Impact catalysts through Q3 2020.

Indications Covered:

  • Acne
  • Acute Myelogenous Leukemia (AML)
  • Angelman Syndrome
  • Bipolar Disorder
  • Cardiac Valve Surgery

COVID-19

  • Diffuse Large B-Cell Lymphoma (DLBCL) - NHL
  • Graft vs. Host Disease (GVHD) - Treatment
  • Hemophilia A
  • Hyperoxaluria
  • Ischemic Stroke
  • Major Depressive Disorder (MDD)
  • Mantle Cell Lymphoma - NHL
  • Multiple Myeloma (MM)
  • Multiple Sclerosis (MS)
  • Myelodysplastic Syndrome (MDS)
  • Osteoarthritis and Osteoarthritis Pain
  • Other Ophthalmological Indications (Ophthalmology)
  • Renal Disease / Renal Failure
  • Rheumatoid Arthritis (RA)
  • Scleroderma
  • Seizure Disorders (Epilepsy)
  • Spinal Muscular Atrophy
Table of Contents
Product Code: #BMT

TABLE OF CONTENTS

  • Contents
  • Summary
  • About the Author
  • Disclaimer
  • Outcomes of Biomedtracker's Large Impact Drug Catalysts from the Q2 2020 Outlook Report
  • Drugs
  • Winlevi / Breezula for Acne (SKIN)
  • Oral Azacitidine for Acute Myelogenous Leukemia (AML) (BMY)
  • OV101 for Angelman Syndrome (OVID)
  • Caplyta for Bipolar Disorder (ITCI)
  • Actemra for COVID-19 (RHHBY)
  • Kevzara for COVID-19 (SNY)
  • MOR208 for Diffuse Large B-Cell Lymphoma (DLBCL) - NHL (MOR)
  • Ryoncil for Graft vs. Host Disease (GVHD) - Treatment (MESO)
  • Roctavian for Hemophilia A (BMRN)
  • Lumasiran for Hyperoxaluria (ALNY)
  • Nuplazid for Major Depressive Disorder (MDD) (ACAD)
  • Nuplazid for Major Depressive Disorder (MDD) (ACAD)
  • KTE-X19 for Mantle Cell Lymphoma - NHL (GILD)
  • Belantamab Mafodotin for Multiple Myeloma (MM) (GSK)
  • Arzerra (Autoimmune) for Multiple Sclerosis (MS) (NVS)
  • ASTX727 for Myelodysplastic Syndrome (MDS) (Otsuka)
  • CNTX-4975 for Osteoarthritis and Osteoarthritis Pain (CNTX)
  • RVL-1201 for Other Ophthalmological Indications (Ophthalmology) (OSMT)
  • Veverimer for Renal Disease / Renal Failure (TCDA)
  • Filgotinib for Rheumatoid Arthritis (RA) (GILD)
  • Lenabasum for Scleroderma (CRBP)
  • Ganaxolone for Seizure Disorders (Epilepsy) (MRNS)
  • Risdiplam for Spinal Muscular Atrophy (RHHBY)
  • Devices
  • Portico TAVI System for Cardiac Valve Surgery (ABT)
  • Ischemic Stroke System (ISS) for Ischemic Stroke (BrainsGate)
  • Deals
  • Alexion to Acquire Portola
  • Neurotrope and Metuchen to Merge
  • Tetraphase to be Acquired by La Jolla Pharmaceuticals
  • Q3 2020 Large Impact Catalysts
Back to Top